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Abstract
Introduction: The symptoms of GH deficiency (GHD) in adults include: abnormalities in body composition, unfavourable lipid profile,
early atherosclerosis and impaired quality of life. The aim of the study was the selection of patients with confirmed severe GHD from
among all the children treated due to GHD, who could benefit from GH therapy continuation in adulthood and the optimization of GH
dosage in young adults with severe GHD.
Material and methods: The study group consisted of 54 young adults (38 male), age 17.6 ± 1.5 years, with childhood-onset GHD, who had
reached final height.
At least 1 month after the GH therapy withdrawal, the second evaluation of GH secretion was performed in all the patients. In 24% of
patients, permanent severe GHD (PSGHD) was confirmed, but a group of 9 patients (4 male) was involved in renewed GH therapy.
Results: The renewed GH therapy gave positive effects, including a significant increase in fat-free mass and a decrease in fat mass, and
a significant decrease in LDL-cholesterol, but connected with an insignificant decrease of HDL-cholesterol serum concentration and im-
proved results of quality of life (QoL) assessment. During the therapy, an insignificant increase of fasting insulin was observed, with no
change in fasting glucose and only a slight increase in HbA1c percentage. A decrease of insulin sensitivity was also observed, but both
insulin secretion and the values of insulin resistance indices still remained within the reference range.
Conclusions: The observed positive effects on body composition, lipid metabolism and QoL, together with the absence of adverse events,
confirm the indications for GH therapy in young adults with severe GHD. (Pol J Endocrinol 2008; 59 (4): 292–300)
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Streszczenie
Wstęp: Niedobór hormonu wzrostu (GHD) u dorosłych charakteryzuje się między innymi: nieprawidłowym składem ciała, zaburzeniami
profilu lipidowego, wczesną miażdżycą oraz pogorszeniem jakości życia. Celem badania było wyodrębnienie pacjentów z ciężkim prze-
trwałym GHD, spośród grupy pacjentów z rozpoznanym w dzieciństwie, leczonym GHD, oraz ocena korzystnego wpływu kontynuacji
terapii GH w życiu dorosłym, a także ustalenie optymalnej dawki GH u młodych dorosłych osób z ciężkim GHD.
Materiał i metody: Badaniem objęto 54 osoby (38 mężczyzn), w wieku 17,6 ± 1,5 roku z rozpoznanym w dzieciństwie GHD, które uzyska-
ły wzrost ostateczny. U wszystkich pacjentów po okresie — co najmniej — 1 miesiąca od zaprzestania leczenia promującego wzrastanie,
przeprowadzono kolejną ocenę wydzielania GH. Ciężką przetrwałą postać GHD stwierdzono u 13 (24%) pacjentów, ale do ponownego
leczenia GH włączono tylko 9 osób (4 mężczyzn).
Wyniki: Obserwowano korzystny wpływ ponownego włączenia terapii GH na skład ciała (znamienny wzrost beztłuszczowej masy ciała
i zmniejszenie tłuszczowej masy ciała), profil lipidowy (znamienne obniżenie stężenia cholesterolu frakcji LDL, jednakże z towarzyszą-
cym nieznamiennym obniżeniem stężenia cholesterolu frakcji HDL) oraz poprawę wyników testów oceniających jakość życia (QoL).
Podczas terapii obserwowano nieznamienny wzrost stężenia insuliny na czczo, bez zmian dotyczących stężenia glukozy na czczo oraz
z jedynie nieznacznym wzrostem odsetka HbA1c. Obserwowano również zmniejszenie insulinowrażliwości, chociaż stężenie insuliny na
czczo i wskaźniki insulinooporności pozostawały w zakresie wartości referencyjnych.
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Introduction
In recent years, severe GHD has been defined as a se-
parate disease, requiring an accurate diagnosis and sub-
stitutive GH therapy administration [1–3]. The symp-
toms of GHD in adults include: abnormal body compo-
sition, reduced bone mineralization, increase of fat body
mass, unfavourable lipid profile, reduced cardiac per-
formance [1]. Long-lasting severe GHD increases morta-
lity rate due to cardiological complications and inciden-
ce of bone fractures, and deteriorates quality of life [4].
Most of the patients treated with GH in childhood
do not require continuation of this therapy as adults.
According to current data, a diagnosis of severe GHD is
confirmed in adulthood only in the minority of patients
with childhood-onset GHD [5–7]. The diagnostic crite-
ria for GHD in adults include clinical signs and symp-
toms of the disease and decreased GH secretion in pro-
vocative tests in patients with previously compensated
cortisol, thyroxin and sex steroid deficiencies, if present
[8]. Due to the appropriate selection of patients requ-
iring continuation of GH therapy in adult life, repeated
evaluation of GH secretion after completion of growth-
promoting therapy should be performed. In accordan-
ce with current recommendations [8–11], the test of
choice in adults is the insulin tolerance test (ITT). In
patients with contra-indications to this test (coronary
heart disease, epilepsy), an alternative test should be
performed. The most reliable test seems to be that with
arginin and somatoliberin (GHRH) administration [12].
The test with clonidine, routinely performed in children,
seems less useful in the diagnosis of GHD in adult pa-
tients [9, 13, 14]. In 1997, during a Conference in Port
Stephens, it was proposed that only one provocative
test be performed to confirm childhood-onset GHD [9].
It seems more appropriate to perform two GH provo-
cative tests in cases of previously diagnosed isolated
GHD, but only one test in patients with multiple pitu-
itary hormone deficiency (MPHD), for the confirmation
of severe GHD in adulthood [11].
The standardized algorithm of repeated evaluation
of the hormonal state of the patient, as well as the re-
commended time-point for renewed GH therapy ad-
ministration and the rules of its continuation, have not
been established so far. Even so, the problem of GH
therapy optimization in adult life remains a subject of
interest for many researchers [9, 10].
Low-dose growth hormone therapy in adults is not
as expensive as in children. Moreover, preventing the
complications of GHD in adult patients is economically
favourable.
The aim of the study was the selection of patients
with confirmed severe GHD from all the subjects who
were treated during childhood with GH for growth
promotion due to GHD, who could benefit from GH
therapy continuation in adulthood as well as optimi-
zing GH dosage and monitoring GH therapy in young
adults with severe GHD.
The Local Ethical Committee approved the study
protocol. Informed consent was obtained from all pa-
tients involved.
Material and methods
Patient recruitment
Analysis comprised 54 young adults (38 male, 16 fema-
le), age 17.6 ± 1.5 years (mean ± SD), with childhood-
onset GHD, who completed GH therapy in our depart-
ment and reached final height (FH) in 2004–2006.
The diagnosis of GHD in childhood was based on
the combination of auxological and hormonal criteria,
i.e. decreased GH peak (below 10 ng/ml) in 2 stimula-
ting tests — with clonidine 0.15 mg/m2 orally and with
either glucagon 30 mg/kg i.m. (not exceeding 1 mg) or
insulin 0.1 IU/kg i.v. In 41 patients, a diagnosis of isola-
ted GHD was established, while the remaining 13 suf-
fered from MPHD. The group with MPHD included
7 children with pituitary stalk interruption syndrome
(PSIS), 3 patients who had had neurosurgery due to cra-
niopharyngioma, 1 boy with isolated severe pituitary
hypoplasia and 2 patients (girls) with severe GHD to-
gether with diabetes insipidus (DI).
All the patients were treated with GH in a dose of
0.18 ± 0.02 mg/kg/week (0.55 ± 0.07 IU/kg/week) and
withdrawn when FH with closed bone epiphyses was
attained.
The patients’ height SD score at therapy onset
(H0SDS) was –2.38 ± 0.71, being improved up to
–1.20 ± 0.75 when FH was achieved. Most of the patients
(47 out of 54) reached FH within normal range. Height
gain was not observed in 7 patients — all with isolated,
partial GHD (GH peak in childhood from 5.6 ng/ml to
7.4 ng/ml) and with normal insulin-like growth factor 1
(IGF-1) secretion before the therapy. At least 1 month
Wniosek: Korzystne zmiany dotyczące składu ciała i profilu lipidów oraz QoL przy braku powikłań wskazują na potrzebę leczenia hor-
monem wzrostu młodych osób dorosłych z ciężkim GHD. (Endokrynol Pol 2008; 59 (4): 292–300)
Słowa kluczowe: ciężki niedobór GH, terapia GH, skład ciała, profil lipidów, metabolizm węglowodanów, insulinooporność, jakość życia
Supported by Ministry of Science and Informatisation, Project 2P05E 113 28.
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after the GH therapy withdrawal, the second evaluation
of GH secretion (retesting) was performed on all the
patients. In patients with either MPHD or GHD coexi-
sting with DI, a single stimulating test - ITT with insu-
lin — in a dose 0.1 IU/kg i.v. was performed, while in
those with previously diagnosed isolated GHD, the
same test was followed by a second one (with arginin
0.5 g/kg and GHRH 1 mg i.v.). The cut-off values of GHD
peak confirming severe GHD in adulthood were as fol-
lows: 3 ng/ml for ITT and 9 ng/ml for the test with argi-
nin and GHRH, according to Aimaretti et al. [12]. The
diagnosis of partial GHD was established when GH peak
was between 3.0 ng/ml and 5.0 ng/ml in ITT or between
9.0 ng/ml and 16.5 ng/ml in the arginin-GHRH test. Hi-
gher GH secretion in stimulating tests was recognised as
normal, leading to the diagnosis of transient GHD.
For the second part of the study, a group of 9 pa-
tients (4 male, 5 female) was included from those with
confirmed permanent severe GHD (PSGHD).
Evaluation during low-dose GH therapy
The therapy with low-dose GH was started after at le-
ast 12 but no more than 36 months from the cessation
of growth-promoting treatment. At the onset of thera-
py, the mean age of the patients was 20.1 ± 2.1 years.
The therapy was continued for 1 year under control of
IGF-1 and IGF-binding protein-3 (IGFBP-3) concentra-
tions. A fixed daily GH dose of 0.3 mg (0.9 IU) was ap-
plied during the entire therapy period in 8 out of 9 pa-
tients, while, in 1 patient, the dose was increased due
to low levels of IGF-1 up to 0.4 mg (1.2 IU), thus leading
to normalisation of IGF-1 secretion.
Before the renewed GH administration, auxologi-
cal, biochemical and hormonal evaluation of the patients
was performed. The patients’ height, weight as well as
waist and hip circumferences were measured. Then
body mass index (BMI) and waist:hip ratio were calcu-
lated. The following parameters of body composition
were assessed: fat mass (FAT), free fat mass (FFM), fat
tissue percentage (FAT%) and total body water (TBW).
Fasting glucose, glycosylated haemoglobin (HbA1c), to-
tal cholesterol (TCh), LDL-cholesterol (LDL-Ch) and
HDL-cholesterol (HDL-Ch), triglycerides (TG), as well
as serum IGF 1 and IGFBP-3 concentrations were me-
asured in the morning hours before the first GH injec-
tion. In all the patients, oral glucose tolerance test
(OGTT) was performed with 75.0 g glucose administra-
tion. Glucose and insulin levels were assessed at 0,
60 and 120 minutes of the test, and insulin resistance
indices, HOMA-IR and IRI according to Belfiore (IRI-
-Belfiore), were calculated [15, 16].
Auxological measurements, glucose metabolism and
lipid profile, together with IGF-1 and IGFBP-3 asses-
sment were repeated after 1 year of GH therapy, accor-
ding to the same protocol as the previous treatment.
Both during the examinations preceding the repeated
GH therapy inclusion and during the period of its admi-
nistration, all the patients received an appropriate sub-
stitution of other deficient hormones, i.e. L-thyroxin,
hydrocortisone, sex steroids and desmopressin, when
necessary. The accuracy of the applied doses of the drugs
was confirmed by appropriate laboratory analyses.
The patients’ quality of life (QoL) was assessed be-
fore and after 1 year of low-dose GH therapy using
a QoL Assessment of GHD in Adults (QoL-AGHDA)
questionnaire, consisting of 25 questions with “yes” or
“no” answers [17]. The higher the number of “yes” an-
swers, the more impaired the patient’s QoL; scores equal
to or over 6 are defined as abnormal.
Laboratory and statistical methods
Growth hormone concentrations were measured by
hGH IMMULITE and DPC assay, calibrated to WHO
IRP 80/505 standard. Serum IGF 1 and IGFBP-3 concen-
trations were assessed by IMMULITE, DPC assays, ca-
librated to WHO NIBSC 1st IRR 87/518 standard for IGF
1 and WHO NIBSC Reagent 93/560 standard for IGFBP-
3. For comparison among children of different age and
sex, IGF-1 concentrations were expressed as IGF-1 SDS,
according to DPC reference data. For calculation of IGF-1/
/IGFBP-3 molar ratio, the following molecular masses
were used: 7.5 kDa for IGF-1 and 42.0 kDa for IGFBP-3
[18]. Biochemical analyses related to the assessment of
glucose metabolism and lipid profile were performed
with standard kits used in routine diagnostics. Body
composition was assessed using the method of bioelec-
trical impedance — Tanita body fat analyser model TBF
410, based on the principles of leg–to–leg bioelectrical
impedance analysis (BIA). A good agreement between
BIA and the dual-energy-X-ray absorptiometry (DEXA)
method for estimating changes in body composition
was described [19].
Statistical analysis included non-parametric tests, as
the distribution of most of the analysed parameters (as-
sessed by Kolmogorow-Smirnov test) was not consistent
with normal distribution. For comparison between the
groups of patients in the same time point, the Mann-
Whitney U test for independent samples was applied,
while comparisons between the results obtained befo-
re and after 1 year of GH administration were perfor-
med using the Wilcoxon signed rank test for depen-
dent samples.
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Results
Growth hormone secretory status after comple-
tion of growth promoting therapy
Permanent severe GHD according to the criteria for
adults (PSGHDA) was confirmed in all the patients with
previous diagnosis of either MPHD or GHD and DI. In
all but one of them, GH peak in ITT was undetectable
(below 0.1 ng/ml) being also extremely low (0.4 ng/ml)
in that last case. Conversely, severe GHD was excluded
in all the patients with childhood-onset isolated GHD.
Moreover, in 37 out of 41 patients in that group, GH
peak in ITT exceeded 5.0 ng/ml, thus remaining within
the normal range for retesting at the attainment of FH,
according to the quoted guidelines [8]. In 30 cases GH
peak in ITT even exceeded 10 ng/ml. It should be stres-
sed that there was no overlap of GH peak in ITT betwe-
en groups and a there was a highly significant differen-
ce between them (p < 0.001).
Arginine-GHRH test was performed in 41 patients
with previous diagnosis of childhood-onset isolated
GHD. In 5 patients, GH peak in the test was between
9 and 16.5 ng/ml (12.1 ± 2.6 ng/ml), while in the rema-
ining 36, GH peak exceeded 16.5 ng/ml, even exceeding
the upper limit of detection (i.e. 40.0 ng/ml) in most cases.
Serum IGF-1 concentration after 1 month from GH
therapy withdrawal was decreased in all the patients
with childhood-onset MPHD, while in those in childho-
od-onset isolated GHD presented either normal (in
38 cases) or only slightly decreased (in the remaining
3 ones). The difference between the Groups presented
highly significant (p < 0.005). Interestingly, the IGF-1/
/IGFBP-3 molar ratio was also significantly (p < 0.001)
higher in the first of the analysed groups. More deta-
iled data are presented in Table I.
Efficacy and safety of low-dose GH therapy
IGF-1 and IGFBP-3 secretion
Before the renewed GH therapy, all the patients with
PSGHDA had extremely low serum IGF-1 concentra-
tions. After 1 year of low-dose GH replacement, a high-
ly significant (p = 0.008) increase of both IGF-1 secre-
tion and its bioavailability (expressed as IGF-1/IGFBP-3
molar ratio) was observed. As mentioned above, IGF-1
levels normalised in all but one patient during admini-
stration of the daily GH dose of 0.3 mg (0.9 IU), while,
in that last case, a slightly higher GH daily dose, i.e.
0.4 mg (1.2 IU) presented an appropriate one. The detailed
data are shown in Table II and Figure 1. All the diffe-
rences between the values obtained at particular analy-
sed time points are marked with * as significant.
Body composition
A positive effect of the renewed GH therapy on the
analysed parameters of body composition was obse-
rved, including a significant increase of FFM (p = 0.050)
and decrease of both fat mass (p = 0.008) and FAT%
(p = 0.020). However, a significant increase of TBW
Table I. Patients’ height, GH secretion and IGF-1 secretion and bioavailability before GH therapy in childhood and after
withdrawal of growth-promoting therapy
Tabela I. Wysokość ciała, wydzielanie GH oraz wydzielanie i biodostępność IGF-1 przed włączeniem leczenia GH w dzieciństwie
oraz podczas ponownej oceny po zakończeniu terapii promującej wzrastanie
Primary diagnosis MPHD (or GHD & DI) Isolated GHD
Before GH therapy in childhood n 13 41
H0SDS –3.39 ± 0.85 –2.25 ± 0.43
GH peak [ng/ml] 2.10 ± 1.36 7.0 ± 2.7
(range: 0.6–4.4) (range: 2.3–9.7)
PSGHDA at rest Confirmed Excluded
1 month after GH therapy withdrawal FH SDS –0.65 ± 0.54 –1.36 ± 0.73
Height SDS gain 2.35 ± 1.16 1.06 ± 0.80
GH peak [ng/ml] in ITT 0.13 ± 0.08 16.3 ± 9.7
(range: 0.1–0.4) (range: 6.3–27.8)
GH peak [ng/ml] not performed 34.8 ± 13.2
in arginin & GHRH test (range: 10.4–> 40.0)
IGF-1 [ng/ml] 51.6 ± 21.2 382.9 ± 152.8
(range: 25.0–93.1) (range: 157.8–856.8)
IGF-1 SDS –5.11 ± 1.32 –0.41 ± 1.15
IGF-1/IGFBP-3 0.09 ± 0.02 0.37 ± 0.14
[molar ratio]
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(p = 0.028) should be considered as the main cause of
an increase of FFM with normal electrolyte concentra-
tions and with no signs and symptoms of pathological
water arrest. The detailed data are presented in Table
III and illustrated in Figures 2–3. Significant differences
are marked with *. Both waist circumference and wa-
ist:hip ratio decreased in all the treated patients; howe-
ver, due to the small number of cases (only 4 male and
5 female) and sex-related normative data, statistical as-
sessment of those changes was not credible.
Lipid profile
Administration of GH led to a decrease of TCh concen-
tration (but only insignificant) together with a very sli-
ght increase if TG level. The positive effect of GH thera-
Figure 1A. Comparison of IGF-1 secretion (expressed as IGF-1 SDS) before and after 1 year of renewed GH treatment. B. Comparison
of IGF-1 bioavailability (expressed as IGF-1/IGFBP-3 molar ratio) before and after 1 year of renewed GH treatment
Rycina 1A. Porównanie wydzielania IGF-1 (wyrażonego wartością IGF-1 SDS) przed i po roku ponownego leczenia GH. B. Porównanie
biodostępności IGF-1 (wyrażonej jako stosunek molowy IGF-1/IGFBP-3) przed i po roku ponownego leczenia GH
Table II. Comparison of IGF-1 secretion and bioavailability
before and after 1 year of renewed GH treatment
Tabela II. Porównanie wydzielania i biodostępności IGF-1
przed i po roku ponownego leczenia GH
Before low-dose After 1 year p
GH therapy of therapy
IGF-1 [ng/ml] 51.3 ± 22.3 186.9 ± 80.6 0.008*
(range: 33.4–93.1) (range: 101–390)
IGF-1 SDS –4.88 ± 2.05 –1.57 ± 1.50 0.008*
IGFBP-3 [mg/ml] 3.2 ± 0.9 4.0 ± 0.8 0.028*
IGF-1/IGFBP-3
[molar ratio] 0.09 ± 0.02 0.26 ± 0.09 0.008*
py on the lipid profile manifested in a significant
(p = 0.038) decrease of LDL-Ch, although connected
with an insignificant decrease of HDL-Ch serum con-
centration. The detailed data are presented in Table IV
and in Figure 4.
Glucose homeostasis and insulin sensitivity
Before GH administration, all the patients had normal
fasting glucose concentrations and relatively low fasting
insulin levels. During the therapy, an insignificant in-
Table III. Comparison of selected parameters of body
composition before and after 1 year of renewed GH treatment
Tabela III. Porównanie wybranych parametrów składu ciała
przed i po roku ponownego leczenia GH
Before renewed After 1 year p
GH therapy of GH therapy
BMI [kg/m2] 23.1 ± 3.1 23.7 ± 3.8 0.317
FAT [kg] 19.6 ± 7.2 18.2 ± 6.9 0.008*
FAT% 26.7 ± 8.6 25.6 ± 8.5 0.020*
FFM [kg] 49.8 ± 6.7 52.4 ± 9.5 0.050*
TBW [kg] 36.6 ± 5.1 38.3 ± 7.0 0.028*
FFM-TBW [kg] 13.2 ± 1.7 14.1 ± 2.5 0.069
males 89.4 ± 11.3 87.9 ± 10.8
females 82.1 ±1 0.9 79.7 ± 10.5
males 0.98 ± 0.17 0.95 ± 0.14
females 0.79 ± 0.12 0.76 ± 0.11
w
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st
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p
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Figure 2A. Comparison of BMI before and after 1 year of renewed GH treatment. B. Comparison of FAT% before and after 1 year of
renewed GH treatment
Rycina 2A. Porównanie BMI przed i po roku ponownego leczenia GH. B. Porównanie FAT% przed i po roku ponownego leczenia GH
Figure 3. Comparison of selected parameters of body composition
before and after 1 year of renewed GH treatment
Rycina 3. Porównanie wybranych parametrów składu ciała przed
i po roku ponownego leczenia GH
Figure 4. Comparison of lipid profile before and after 1 year of
renewed GH treatment
Rycina 4. Porównanie profilu lipidów przed i po roku ponownego
leczenia GH
crease of fasting insulin was observed, with no change
in fasting glucose and only a slight increase in HbA1c
percentage. A decrease of insulin sensitivity was also
observed but both insulin secretion and the values of
insulin resistance indices still remained within the re-
ference range. Interestingly, an increase of IRI-Belfiore
(derived from OGTT) presented significantly, while that
of HOMA-IR (calculated from fasting glucose and in-
sulin levels) was insignificant. Moreover, none of the
patients discontinued the study or had to reduce GH
dose. The detailed data concerning glucose metabolism
are presented in Table V and in Figures 5–6.
Table IV. Comparison of selected parameters of lipid profile
before and after 1 year of renewed GH treatment
Tabela IV. Porównanie wybranych parametrów profilu przed
i po roku ponownego leczenia GH
Before renewed After 1 year p
GH therapy of GH therapy
TCh [mg/dl] 184±43 17240 0.155
HDL [mg/dl] 58±15 55±17 0.086
LDL [mg/dl] 114±40 9934 0.038*
TG [mg/dl] 83±43 87±24 0.477
A B
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Table V. Comparison of fasting glucose, insulin and HbA1c
concentrations as well as insulin resistance indices (HOMA-
IR and IRI-Belfiore) before and after 1 year of renewed GH
treatment
Tabela V. Porównanie stężenia glukozy i insuliny na czczo
oraz HbA1c i wskaźników insulinooporności (HOMA-IR i IRI-
Belfiore) przed i po roku ponownego leczenia GH
Before renewed After 1 year p
GH therapy of GH therapy
Fasting 71 ± 7 73 ± 9 0.441
glucose [mg/dl]
Fasting 2.8 ± 1.4 4.4 ± 2.8 0.173
insulin [mU/ml]
HbA1c [%] 4.9 ± 0.3 5.1 ± 0.3 0.345
HOMA-IR 4.88 ± 2.65 8.26 ± 6.05 0.116
IRI-Belfiore 0.50 ± 0.26 0.92 ± 0.32 0.036*
Quality of life
After the period of GH therapy withdrawal, i.e. just be-
fore the onset of low-dose GH treatment, the mean QoL-
AGHDA score was 11.2 (range: 6–14) and decreased si-
gnificantly (p < 0.05) to 5.6 (range: 3–8), thus confir-
ming the improvement of QoL during GH administra-
tion. The sex-related differences in QoL could not be
analysed due to the small number of patients.
Discussion
The positive effects of low-dose GH therapy in adults
with severe GHD on body composition, lipid metabo-
lism and QoL are well known. In 2007 Svensson at al.
[20] published data on the metabolic and clinical respon-
se to one-year GH replacement therapy in 380 adults
with GHD. The inclusion criteria in that study (i.e. GH
peak in ITT below 3 ng/ml) were similar to those ap-
plied to the current study. The initial GH dose was lo-
wer than that administered in our patients; however, it
increased during the therapy up to a dose slightly hi-
gher than that used by us. An improvement in all the
analysed parameters of body composition, lipid profile
and QoL during GH administration was observed, and
a negative correlation between the severity of distur-
bances and the effectiveness of GH therapy was found.
The results of a one-year replacement therapy study
with a fixed low dose of GH, published by Boguszew-
ski at al. in 2005 were similar [21]. In both studies, no
serious side effects were reported. Our results agree
with previous observations. It should be stressed, ho-
wever, that the patients recruited to the current study
were younger (mean age: 20.1 years) than in the cited
studies — 53.8 years [20] and 40.6 years [21] and the
time interval from cessation of growth promoting GH
administration was relatively short in our group of pa-
tients. It should also be stressed that, despite younger
age and short period with no GH therapy, similar ab-
normalities as found in older patients were observed in
the young adults involved in our study. Moreover, the
effect of GH therapy administered again in a low dose
also presented similarly to those in older age groups of
GH-deficient adults.
Both at therapy onset and after one year, our patients
had normal BMI, in contrast to the patients reported by
Boguszewski at al. [21], who were overweight, probably
due to a longer period of untreated severe GHD. Howe-
ver, positive effects of GH administration on lean and fat
body mass was observed in both groups.
In our study, lipid profile was normal both before
and after one year of GH therapy, but a significant de-
Figure 5. Comparison of glucose, insulin and HbA1c concentrations before and after 1 year of renewed GH treatment
Rycina 5. Porównanie stężenia glukozy, insuliny i HbA1c przed i po roku ponownego leczenia GH
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crease in LDL-Ch and an insignificant decrease in TCh
was observed. In most trials [22–25], a reduction in TCh
and LDL-Ch was reported with no significant effect on
HDL-Ch and TG levels. In younger patients, however,
the initial lipid parameters presented as either normal
or less disturbed [21] compared to older patients [20].
The above-mentioned observations indicate a worse-
ning lipid metabolism in adult patients with untreated
severe GHD, while the improvement of lipid profile
during low-dose GH therapy in young adults with se-
vere GHD speaks for the necessity of continuation of
the therapy after completion of growth promotion.
There is no doubt that at the moment of final height
achievement, bone mass accrual is still not complete.
Thus, GH therapy withdrawal in the patient with seve-
re GHD at that time point leads to a reduction in peak
bone mass. The legitimacy for GH therapy continuation
in young adults at final height has recently been accep-
ted [10, 11]. It was even proposed in Consensus guide-
lines from 2007 [11] that GH secretion be reassessed
twice: once just after completion of linear growing and,
in selected cases, for a second time after completion of
somatic growth, at the age of approximately 25 years.
Moreover, the cut-off value of GH peak in ITT in the
transition period (in first re-evaluation) was recommen-
ded at the level of 6 ng/ml. Different cut-off values for
the arginine-GHRH test, with respect to the patient’s
BMI, were also suggested, with higher cut-off levels for
lean patients (11 ng/ml) than for obese patients (8 ng/ml
for BMI 25–30 kg/m2 and 4 ng/ml for BMI over 30 kg/m2)
[11]. Retrospective analysis of our group showed that
Figure 6A. Comparison of HOMA insulin resistance index (HOMA-IR) before and after 1 year of renewed GH treatment. B. Comparison
of insulin resistance index acc. to Belfiore (IRI-Belfiore) before and after 1 year of renewed GH treatment
Rycina 6A. Porównanie wskaźnika insulinooporności HOMA (HOMA-IR) przed i po roku ponownego leczenia GH. B. Porównanie
wskaźnika insulinooporności według Belfiore (IRI-Belfiore) przed i po roku ponownego leczenia GH
all the 41 patients with non-confirmed PSGHDA had
GH peak in ITT over 6.0 ng/ml. Among them, GH peak
in the arginine-GHRH test ranged from 10.4 ng/ml to
over 40.0 ng/ml, although remaining within the normal
range according to the modified criteria of test inter-
pretation.
The positive effect of GH replacement on QoL in
adults with severe GHD is unquestionable [21]. A wor-
sening of QoL after completion of growth-promoting
GH therapy was reported by most of our patients, and
the considerable improvement of QoL was confirmed
by the scores of QoL-AGHDA. Interestingly, QoL pre-
sented a decrease even in young adults with no severe
metabolic abnormalities and after a relatively short pe-
riod of GH therapy discontinuation.
Neither our results nor any from previous studies
[21, 22, 26–28] report severe adverse effects of low-dose
GH therapy, including disturbances in glucose metabo-
lism and insulin resistance. However, the unfavourable
effect on insulin sensitivity should be taken into acco-
unt during GH administration. According to our results,
it seems that OGTT with calculation of IRI-Belfiore al-
lows earlier detection of increased insulin resistance
than assessment of fasting glucose and insulin levels.
Conclusions
The observed positive effects on body composition, li-
pid metabolism and QoL, together with the absence of
adverse events, confirm the indications to GH therapy
in young adults with severe GHD.
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